Cefalotin is a semisynthetic, beta-lactam, first-generation cephalosporin antibiotic with bactericidal activity. Cefalotin is a drug which is used to prevent infection during surgery and to treat many kinds of infections of the blood, bone or joints, respiratory tract, skin, and urinary tract.
Cefalexin is the first of the first generation cephalosporins. This antibiotic contains a beta lactam and a Dihydrothiazide. Cefalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis. Cefalexin was approved on 4 January 1971.
Cefadroxil is the anhydrous form of Cefadroxil, a semisynthetic first-generation cephalosporin with antibacterialactivity. Cefadroxil is used to treat certain infections caused by bacteria such as infections of the skin, throat, tonsils, and urinarytract.
Cefaclor is a beta-lactam, second-generation cephalosporin with antibacterialactivity is a second generation cephalosporinantibiotic used to treat certain bacterialinfections such as pneumonia and infections of the ear, lung, skin, throat, and urinary tract.
Capecitabine is a FluoropyrimidineCarbamate belonging to the class of AntineoplasticAgents called Antimetabolites. Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastaticbreast and colorectalcancers. Capecitabine was patented in 1992 and approved for medical use in 1998. It is on the WorldHealthOrganization's List of Essential Medicines.
Canagliflozin is the anhydrous form of canagliflozin, a C-glucoside with a thiophene ring that is an orally available inhibitor of sodium-glucose transporter 2 (SGLT2) with antihyperglycemic activity. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type2diabetesmellitus.
Cabazitaxel is a semi-synthetic derivative of the natural Taxoid 10-deacetylbaccatin III with potential antineoplastic activity. Cabazitaxel is used to treat people with prostatecancer that has progressed despite treatment with docetaxel. It was approved by Food and Drug Administration (FDA) in 2010.
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The boron atom in bortezomib binds the catalytic site of the 26S proteasome with high affinity and specificity. In May 2003, bortezomib became the first anticancerproteasome inhibitor that was approved by the FDA.
